Fisher Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Fisher Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$874K	Buy	+65,751	New	+$641K	﹤0.01%	721

Other funds holding FDMT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PWM

Perigon Wealth Management San Francisco, California $6.36B AUM 28.76% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Fisher Asset Management's FDMT Position: Q2 2026 in Review

Fisher Asset Management opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 65,751 shares worth $874K. The stake represents ﹤0.01% of the portfolio and ranks #721 among its holdings.

50 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Fisher Asset Management held 65,751 shares of 4D Molecular Therapeutics worth $874K as of Q2 2026.
4D Molecular Therapeutics was a new Fisher Asset Management position in Q2 2026.
4D Molecular Therapeutics made up ﹤0.01% of Fisher Asset Management's portfolio in Q2 2026, its #721 holding.
50 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.